Comparison of the Safety and Efficacy between Preserved and Preservative-Free Latanoprost and Preservative-Free Tafluprost
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Joon Mo | - |
dc.contributor.author | Park, Sang Woo | - |
dc.contributor.author | Seong, Mincheol | - |
dc.contributor.author | Ha, Seung Joo | - |
dc.contributor.author | Lee, Ji Woong | - |
dc.contributor.author | Rho, Seungsoo | - |
dc.contributor.author | Lee, Chong Eun | - |
dc.contributor.author | Kim, Kyoung Nam | - |
dc.contributor.author | Kim, Tae-Woo | - |
dc.contributor.author | Sung, Kyung Rim | - |
dc.contributor.author | Kim, Chan Yun | - |
dc.date.accessioned | 2021-09-10T05:47:02Z | - |
dc.date.available | 2021-09-10T05:47:02Z | - |
dc.date.issued | 2021-06 | - |
dc.identifier.issn | 1424-8247 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/18797 | - |
dc.description.abstract | In this study, we investigated the effect of preservative-free (PF) 0.0015% tafluprost (TA), to the preservative containing (PC) and the PF 0.005% latanoprost (LA) in Korean subjects. This study was conducted as a multi-center, randomized, investigator-blind, active controlled, parallel-group, clinical trial in adult patients (>= 19 years) with open-angle glaucoma (OAG) and ocular hypertension (OHT). After a washout period, patients with an IOP between 15 and 35 mmHg were enrolled and evaluated the efficacy, safety, and compliance at 4, 8 and 12 weeks after the first administration. A total of 137 OAG and OHT patients were randomized. Statistically significant reductions in IOP were observed in all groups. Twelve weeks after each eye drop instillation, the mean IOP reduction was -4.59 +/- 2.70 mmHg (-24.57 +/- 13.49%) in the PC-LA group, -4.52 +/- 2.17 mmHg (-24.41 +/- 11.38%) in the PF-LA, and -3.14 +/- 2.83 mmHg (-17.22 +/- 14.57%) in the PF-TA group. The PF-LA showed significantly better responsiveness than did PF-TA. PF-LA was better tolerated than was PC-LA. There were no adverse events that led to cessation of eye drop use in any of the groups. In conclusion, IOP decreased similarly across the groups. PF-LA may provide a good choice for OAG patients with ocular surface diseases. | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | Multidisciplinary Digital Publishing Institute (MDPI) | - |
dc.title | Comparison of the Safety and Efficacy between Preserved and Preservative-Free Latanoprost and Preservative-Free Tafluprost | - |
dc.type | Article | - |
dc.publisher.location | 스위스 | - |
dc.identifier.doi | 10.3390/ph14060501 | - |
dc.identifier.scopusid | 2-s2.0-85107512239 | - |
dc.identifier.wosid | 000666066200001 | - |
dc.identifier.bibliographicCitation | Pharmaceuticals, v.14, no.6 | - |
dc.citation.title | Pharmaceuticals | - |
dc.citation.volume | 14 | - |
dc.citation.number | 6 | - |
dc.type.docType | Article | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Chemistry, Medicinal | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.subject.keywordPlus | OCULAR SURFACE DISEASE | - |
dc.subject.keywordPlus | OPEN-ANGLE GLAUCOMA | - |
dc.subject.keywordPlus | CARBOMER GEL | - |
dc.subject.keywordPlus | CONTACT TIME | - |
dc.subject.keywordPlus | TEARS | - |
dc.subject.keywordAuthor | ocular surface discomfort | - |
dc.subject.keywordAuthor | dry eye | - |
dc.subject.keywordAuthor | glaucoma | - |
dc.subject.keywordAuthor | prostaglandin analogue | - |
dc.subject.keywordAuthor | latanoprost | - |
dc.subject.keywordAuthor | tafluprost | - |
dc.subject.keywordAuthor | intraocular pressure | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(31538) 22, Soonchunhyang-ro, Asan-si, Chungcheongnam-do, Republic of Korea+82-41-530-1114
COPYRIGHT 2021 by SOONCHUNHYANG UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.